Eculizumab in secondary atypical haemolytic uraemic syndrome.

Nephrol Dial Transplant · 2017 · PMC5410989 · PMID 28339660

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

almost significantno p-value reported

As shown in Table 7 , an almost significant trend towards a longer delay in eculizumab therapy and a significantly shorter duration of treatment were observed among our non-responder patients.

also in 1,858 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.